Seeking Alpha
View as an RSS Feed

Ian Bezek  

View Ian Bezek's Comments BY TICKER:
Latest  |  Highest rated
  • Investing In Multinationals Is Not The Same As Investing Internationally [View article]
    You're right on that TF17. Given that Japan and Europe both have horrendous demographic outlooks going forward, there is a decent chance of this continuing as well. If you want GDP growth out of Europe or (shudder) Japan, how are you going to get it?

    Emerging markets is a whole other kettle of fish. There is plenty of growth, the question is of harnessing it well and not getting caught in too many frauds or political panics along the way.
    Jun 29, 2015. 07:04 PM | 1 Like Like |Link to Comment
  • Profit From The Pharma Craze: Sell Gilead, Buy Taro [View article]
    Thanks Joseph!
    Jun 29, 2015. 06:48 PM | Likes Like |Link to Comment
  • Kinder Morgan: Bear Attacks Are Misguided And Won't Succeed, Here's Why [View article]
    When people have already developed religious fervor for a stock, they tend to not have much capital left on the sideline to buy more when it corrects...
    Jun 29, 2015. 06:22 PM | 1 Like Like |Link to Comment
  • Kinder Morgan: Bear Attacks Are Misguided And Won't Succeed, Here's Why [View article]
    24% a year CAGR here? I doubt it.
    Jun 29, 2015. 06:20 PM | 1 Like Like |Link to Comment
  • Kinder Morgan: Bear Attacks Are Misguided And Won't Succeed, Here's Why [View article]
    Chancer: That comment was comedic gold. Big thumbs up.
    Jun 29, 2015. 06:19 PM | 1 Like Like |Link to Comment
  • Investing In Multinationals Is Not The Same As Investing Internationally [View article]
    I see US beating Developed markets by 1% and losing to emerging by 5% over a 40 year period. That seems to offer strong support to the idea of going international, particularly emerging.

    The last few years the US has benefitted from an unprecedented tech boom, which may or may not repeat. Who knows, perhaps some other country will revolutionize something in the future as well? The US has also benefitted recently from massive PE expansion, something which could very well contract again in the future.
    Jun 29, 2015. 05:19 PM | Likes Like |Link to Comment
  • Profit From The Biotech Craze: Long Gilead Sciences And Short Taro [View article]
    Excellent comment.
    Jun 26, 2015. 01:17 PM | 1 Like Like |Link to Comment
  • Profit From The Pharma Craze: Sell Gilead, Buy Taro [View article]
    "My advice to you should you develop Toe Nail Fungus would be to call a Tow Truck"

    Thanks, I'll be sure to keep that in mind.
    Jun 26, 2015. 12:38 PM | 1 Like Like |Link to Comment
  • Warren Buffett's Berkshire Hathaway At ½ Price [View article]
    Plus you pay a higher tax rate selling GLD than BRK. Collectable.
    Jun 25, 2015. 03:46 PM | 1 Like Like |Link to Comment
  • Is Lexington Realty's 7.5% Yield Too Good To Be True? [View article]
    Ex-div is tomorrow. As such, could see a print toward 8.60-8.70 tomorrow. Pretty nice price for accumulation.
    Jun 25, 2015. 12:26 PM | 1 Like Like |Link to Comment
  • Profit From The Pharma Craze: Sell Gilead, Buy Taro [View article]
    GILD is the largest holding (8%) of IBB. While GILD may outperform IBB in a sector contraction, if IBB goes down, GILD is likely to slump with it, at least for awhile.
    Jun 25, 2015. 11:56 AM | Likes Like |Link to Comment
  • Searching For The Dividend Aristocrats Of Tomorrow: 2 Decade Edition [View article]
    Refiners are a highly (!) cyclical business. It's not abnormal for them go up 500%, drop 80%, and then go up 500% again. Look at a long-term chart of WNR for example.

    Alas, they'll never be dividend aristocrats because they always cut/freeze the dividends during the low tides for refining.

    That's not to say don't buy them, but they struggle as buy/hold investments -- absurdly high beta and the dividend is only grown in good times.
    Jun 25, 2015. 10:51 AM | Likes Like |Link to Comment
  • Trading The VIX: I Want Volatility With My Volatility ETF [View article]
    50,000 shares avg vol x $50 share price. $2.5 million daily vol -- plenty for non institutional entities.
    Jun 25, 2015. 10:43 AM | Likes Like |Link to Comment
  • Profit From The Biotech Craze: Long Gilead Sciences And Short Taro [View article]
    Excellent questions alpha. If generics were such an easy business, you'd think there'd be more competition, right?
    Jun 24, 2015. 11:42 PM | 4 Likes Like |Link to Comment
  • Profit From The Biotech Craze: Long Gilead Sciences And Short Taro [View article]
    More so than TARO. Look at the profit margins. TARO due to having a specialty earns far higher returns than its peers. Closer to GILD than the other generics.

    Gross Margin:

    GILD 86%

    TARO 76%

    TEVA 55%
    MYL 46%

    If Mr. Poulos wants to make a more effectual rebuttal he could delve into the derma arena rather than just saying: generics bad, TARO generic = TARO bad as is the idea here.

    If anything this rebuttal makes the case for TARO. If Wall Street is dismissing TARO thinking it's just another MYL, that would further help explain why it's undervalued.
    Jun 24, 2015. 09:43 PM | 5 Likes Like |Link to Comment
COMMENTS STATS
2,055 Comments
2,334 Likes